Latest Publishing News

Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

Woodside Energy posted a solid first quarter with strong asset reliability, an 11% lift in realised prices, and key projects like Scarborough nearing completion. Production dipped due to cyclones but full-year guidance remains steady.

Image Resources delivered a solid first quarter at its Atlas project with production and sales within guidance, operating costs under forecast, and secured a six-month debt repayment holiday. Development advances on multiple mineral sands projects and maiden gold resource drilling is underway.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

Streamplay Studio delivers a fourth consecutive quarter of positive cash flow, underpinned by steady publishing revenues and strategic platform growth in new regions.

29Metals has delivered strong final drill results from its 2025 program at Golden Grove, revealing high-grade copper and zinc intercepts that promise to boost mineral resources and mine flexibility. The company plans a significant exploration budget increase for 2026 to capitalize on this momentum.

Metals Australia’s new PEA for its Quebec Battery Anode Material Refinery reveals robust economics with a $2.05 billion USD pre-tax NPV and a 25.6% IRR, underpinning plans for a final feasibility study.